Bayesian adaptive clinical trials: A dream for statisticians only?

Statistics in Medicine

Volumn 31, Issue 11-12, 2012, Pages 1002-1013

  Chevret, Sylvie ^a,b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Adaptive designs; Bayesian clinical trials; Bibliometrics

Indexed keywords

ARTICLE; BAYES THEOREM; BIBLIOGRAPHIC DATABASE; BIBLIOMETRICS; BIOSTATISTICS; CLINICAL TRIAL (TOPIC); MEDICAL LITERATURE; STATISTICAL ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW;

BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; RESEARCH DESIGN;

EID: 84861200623     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4363     Document Type: Article

References (57)

1. Jones D. Adaptive trials receive boost. Nature Reviews Drug Discovery 2010; 9: 345-348.
2. Chang M, Chow SC, Pong A. Adaptive design in clinical research: issues, opportunities, and recommendations. Journal of Biopharmaceutical Statistics 2006; 16: 299-309.
3. Chow SC, Chang M. Adaptive design methods in clinical trials. Chapman and Hall: Boca Raton, 2007.
4. Wei LJ. The adaptive biased coin design for sequential experiments. Annals of Statistics 1978; 6: 92-100.
5. Coffey CS, Kairalla JA. Adaptive clinical trials: progress and challenges. Drugs in R&D 2008; 9: 229-242.
6. Hunge HMJ, O'Neill RT, Wang SJ, Lawrence J. A regulatory view on adaptive/flexible clinical trial design. Biometrical Journal 2006; 48: 565-573.
7. Vandemeulebroecke M. Group Sequential and Adaptive Designs - A Review of Basic Concepts and Points of Discussion. Biometrical Journal 2008; 50: 541-557.
8. Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian adaptive methods for clinical trials. Chapman & Hall: Boca Raton, 2010.
9. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and Health-care Evaluation. Wiley: Chichester, 2004.
10. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C. Risks and benefits of Phase 1 Oncology Trials, 1991 through 2002. New England Journal of Medicine 2005; 352: 895-904.
11. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. New England Journal of Medicine 2005; 352: 930-932.
12. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46: 33-48.
13. The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. Point to Consider on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan. Technical report. CPMP/EWP/2459/02: London, 2002.
14. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian Approaches to Randomized Trials. Journal of the Royal Statistical Society Series A-Statistics in Society 1994; 157: 357-387.
15. Campbell G. The experience in the FDA's Center for Devices and Radiological Health with Bayesian strategies. Clinical Trials 2005; 2: 359-363.
16. Berry D. Bayesian Clinical Trials. Nature Reviews Drug Discovery 2006; 5: 27-36.
17. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri F, Porter A. Translation of Innovative Designs Into Phase I Trials. Journal of Clinical Oncology 2007; 25: 4982-4986.
18. Palmer CR, Rosenberger WF. Ethics and practice: Alternative designs for phase III randomized clinical trials. Controlled Clinical Trials 1999; 20: 172-186.
19. Altman DG, Goodman SN. Transfer of Technology from Statistical Journals to the Biomedical Literature. Past Trends and Future Predictions. Journal of the American Medical Association 1994; 272: 129-132.
20. Donner A. A Bayesian-Approach to the interpretation of Subgroup Results in Clinical Trials. Journal of Chronic Diseases 1982; 35: 429-435.
21. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G. AIR2 Trial Study Group. Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine 2010; 181: 116-124.
22. Wang YG. Sequential Allocation in Clinical Trials. Communications in Statistics-Theory and Methods 1991; 20: 791-805.
23. Andersen J, Faries D, Tamura R. A Randomized Play-The-Winner Design ForMultiarm Clinical Trials. Communications in Statistics-Theory and Methods 1994; 23: 309-323.
24. Tamura RN, Faries DE, Andersen JS, Heiligenstein JH. A Case-Study of an Adaptive Clinical Trial in the Treatment of out-patients with depressive Disorder. Journal of the American Statistical Association 1994; 89: 768-776.
25. Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in PhaseI oncology trials. Biometrics 2003; 59: 487-496.
26. Thompson SG, Warn DE, Turner RM. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale. Statistics in Medicine 2004; 23: 389-410.
27. Turner RM, Omar RZ, Thompson SG. Modelling multivariate outcomes in hierarchical data, with application to cluster randomised trials. Biometrical Journal 2006; 48: 333-345.
28. Thompson SG, Warn DE, Turner RM. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale. Statistics in Medicine 2004; 23: 389-410.
29. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials 2009; 6: 205-216.
30. Gurrin LC, Burton PR. A comparison of the imprecise beta class, the randomized play-the-winner rule and the triangular test for clinical trials with binary responses. Australian & New Zealand Journal of Statistics 2007; 49: 25-35.
31. Atkinson AC, Biswas A. Bayesian adaptive biased-coin designs for clinical trials with normal responses. Biometrics 2005; 61: 118-125.
32. Cheng Y, Berry DA. Optimal adaptive randomized designs for clinical trials. Biometrika 2007; 94: 673-689.
33. Stallard N, Posch M, Friede T, Koenig F, Brannath W. Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine 2009; 28: 1321-1338.
34. Morita S, Sakamoto J. Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design. Pharmaceutical Statistics 2006; 5: 109-118.
35. Thall PF, Inoue LYT, Martin TG. Adaptive decision making in a lymphocyte infusion trial. Biometrics 2002; 58: 560-568.
36. Bandyopadhyay U, Biswas A, Bhattacharya R. A Bayesian adaptive design for two-stage clinical trials with survival data. Lifetime Data Analysis 2009; 15: 468-492.
37. Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine 2005; 24: 1947-1964.
38. Biswas A, Angers JF. A Bayesian adaptive design in clinical trials for continuous responses. StatisticaNeerlandica 2002; 56: 400-414.
39. Dawson R, Lavori PW. Sequential causal inference: Application to randomized trials of adaptive treatment strategies. Statistics in Medicine 2008; 27: 1626-1645.
40. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Statistics in Medicine 2009; 28: 1680-1689.
41. Rosenberger W, Lachin J. The use of response-adaptive designs in clinical trials. Controlled Clinical trials 1993; 14: 471-484.
42. Mahajan R, Gupta K. Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies. Journal of Pharmacy and BioAllied Sciences 2010; 2: 307-313.
43. Feng H, Shao J, Chow SC. Adaptive group sequential test for clinical trials with changing patient population. Biopharmaceutical Statistics 2007; 17: 1227-1238.
44. Morgan CC. Sample size re-estimation in group-sequential response-adaptive clinical trials. Statistics in Medicine 2003; 22: 3843-3857.
45. Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Controlled Clinical Trials 2003; 24: 506-522.
46. Pibouleau L, Chevret S. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. Journal of Clinical Epidemiology 2011; 64: 270-279.
47. Chen MH, Ibrahim JG. The relationship between the power prior and hierarchical models. Bayesian Analysis 2006; 1: 551-574.
48. Westover MB, Westover KD, Bianchi MT. Significance testing as perverse probabilistic reasoning. BMC Medicine 2011; 9(20). DOI: 10.1186/1741-7015-9-20.
49. Wang M, Wu YC, Tsai GF. A regulatory view of adaptive trial design. Journal of the Formosan Medical Association 2008; 107: 3-8.
50. Chevret S. Statistical Methods for Dose-Finding Experiments. Wiley: Chichester, 2006.
51. ICH E9 Expert Working Group. Statistical Principles for Clinical Trials: ICH Harmonized Tripartite Guideline. Statistics in Medicine 1999; 18: 1905-1942.
52. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. Biotechnology Law Report 2010; 29: 197-215. DOI: 10.1089/blr.2010.9977.
53. Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clinical Trials 2010; 7: 167-173.
54. Johnson VE, Cook JD. Bayesian Design of Single-arm Phase II Clinical Trials with Continuous Monitoring. Clinical Trials 2009; 6: 217-226.
55. Ashby D. Bayesian statistics in medicine: A 25 year review. Statistics in Medicine 2006; 25: 3589-3631.
56. Bolstad WM. Introduction to Bayesian Statistics. Wiley: Hoboken, 2007.
57. Navarro A, Martin M. Scientific production and international collaboration in occupational health, 1992-2001. Scandinavian Journal of Work, Environment & Health 2004; 30: 223-233.